Tobias Sejbaek

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6071990/publications.pdf

Version: 2024-02-01

23 papers 430 citations

1039880 9 h-index 20 g-index

24 all docs

24 docs citations

24 times ranked 849 citing authors

#	Article	IF	CITATIONS
1	Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment $na\tilde{A}^-$ ve relapsing MS patients. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, jnnp-2019-321321.	0.9	66
2	An observational study of alemtuzumab following fingolimod for multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e320.	3.1	51
3	Practice effect in Symbol Digit Modalities Test in multiple sclerosis patients treated with natalizumab. Multiple Sclerosis and Related Disorders, 2016, 10, 116-122.	0.9	48
4	Comparative effectiveness of teriflunomide and dimethyl fumarate. Neurology, 2019, 92, e1811-e1820.	1.5	36
5	Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 56, 103251.	0.9	36
6	Real-life persistence and tolerability with dimethyl fumarate. Multiple Sclerosis and Related Disorders, 2018, 24, 42-46.	0.9	31
7	Orthologous proteins of experimental de- and remyelination are differentially regulated in the CSF proteome of multiple sclerosis subtypes. PLoS ONE, 2018, 13, e0202530.	1.1	28
8	Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2022, 60, 103729.	0.9	24
9	The Urine Proteome Profile Is Different in Neuromyelitis Optica Compared to Multiple Sclerosis: A Clinical Proteome Study. PLoS ONE, 2015, 10, e0139659.	1.1	15
10	Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry. PLoS ONE, 2021, 16, e0250820.	1.1	12
11	Omics-Based Approach Reveals Complement-Mediated Inflammation in Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS). Frontiers in Immunology, 2018, 9, 741.	2.2	10
12	CSF proteome in multiple sclerosis subtypes related to brain lesion transcriptomes. Scientific Reports, 2021, 11, 4132.	1.6	10
13	Diroximel fumarate in the treatment of multiple sclerosis. Neurodegenerative Disease Management, 2020, 10, 267-276.	1.2	8
14	Comparison of neurofilament light chain results between two independent facilities. BMJ Neurology Open, 2020, 2, e000063.	0.7	7
15	Serum levels of neurofilament light chain, neuron-specific enolase and S100 calcium-binding protein B during acute bacterial meningitis: a prospective cohort study. Infectious Diseases, 2021, 53, 409-419.	1.4	7
16	<p>Patient Attitudes to Routine Cognitive Testing in Multiple Sclerosis</p> . Patient Preference and Adherence, 2020, Volume 14, 693-704.	0.8	6
17	Elevated Neurofilament Light Chain in Cerebrospinal Fluid and Plasma Reflect Inflammatory MRI Activity in Neurosarcoidosis. Brain Sciences, 2021, 11, 238.	1.1	6
18	The levels of the serine protease HTRA1 in cerebrospinal fluid correlate with progression and disability in multiple sclerosis. Journal of Neurology, 2021, 268, 3316-3324.	1.8	6

TOBIAS SEJBAEK

#	Article	IF	CITATIONS
19	Inflammatory profiles in plasma and cerebrospinal fluid of patients with neurosarcoidosis. Journal of Neuroimmunology, 2022, 367, 577849.	1.1	6
20	Reliability and Validity of a Danish Version of the Multiple Sclerosis Neuropsychological Screening Questionnaire. International Journal of MS Care, 2018, 20, 49-54.	0.4	5
21	MIF in the cerebrospinal fluid is decreased during relapsing-remitting while increased in secondary progressive multiple sclerosis. Journal of the Neurological Sciences, 2022, 439, 120320.	0.3	5
22	Long-term structural retinal changes in patients with optic neuritis related to multiple sclerosis. Clinical Ophthalmology, 2017, Volume 11, 1519-1525.	0.9	4
23	A prospective, one-year follow-up study of patients newly diagnosed with neurosarcoidosis. Journal of Neuroimmunology, 2022, 369, 577913.	1.1	2